Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia

British Journal of Haematology

Volumn 123, Issue 1, 2003, Pages 49-59

  Garg, Mamta ^a   Moore, Helen ^a   Tobal, Khalid ^a   Liu Yin, John A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acute leukaemia; Minimal residual disease; Prognosis; Reverse transcription polymerase chain reaction; WT1 gene transcript

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUSION GENE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SAMPLING; SIGNAL TRANSDUCTION; STANDARD; SURVIVAL RATE; TITRIMETRY;

ADOLESCENT; ADULT; AGED; BONE MARROW EXAMINATION; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; GENES, ABL; GENETIC MARKERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; WT1 PROTEINS;

EID: 0141595906     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04552.x     Document Type: Article

References (30)

1. Baird, P.N. & Simmons, P.J. (1997) Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Experimental Hematology, 25, 312-320.
2. Bergmann, L., Meithing, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E. & Hoelzer, D. (1997) High levels of Wilm's tumor gene (WT1) mRNA in acute myeloid leukemia are associated with a worse long-term outcome. Blood, 90, 1217-1225.
3. Brieger, J., Weidmann, E., Fenchel, K., Mitrou, P.S., Hoelzer, D. & Bergmann, L. (1994) The expression of Wilms' tumor gene in acute myeloid leukemias as a possible marker for leukemic blast cells. Leukemia, 8, 2138-2143.
4. Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., Amabile, M., Terragna, C., Ruggeri, D., Piccaluga, P.P., Isidori, A., Malagola, M., Baccarani, M., Tura, S. & Martinelli, G. (2002) Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 99, 443-449.
5. Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yegen H. & Lewis, W.H. (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11, Wilm's tumor locus. Cell, 60, 509-520.
6. Cave, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 339, 591-598.
7. Chomzynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156.
8. Cilloni, D., Gottardi, E., De Micheli, D., Serra, A., Volpe, G., Messa, F., Rege-Cambrin, G., Guerrasio, A., Divona, M., Lo Coco, F. & Saglio, G. (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 16, 2115-2121.
9. Clarkson, T., Gussow, D., Jones, P.T. (1991) General application of PCR to gene cloning and manipulation. In: PCB, A Practical Approach. (ed. by M.J. McPherson, P. Quirke & G.R. Taylor), p. 207. Oxford University Press, New York.
10. Cross, N.C., Feng, L., Chase, A., Bungey, J., Hughes, T.P. & Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 1929-1936.
11. Gaiger, A., Schmid, D., Heinze, G., Linnerth, B., Greinix, H., Kalhs, P., Tisljar, K., Priglinger, S., Laczika, K., Mitterbauer, M., Novak, M., Mitterbauer, G., Mannhalter, C., Haas, O.A., Lechner, K. & Jäger, U. (1998) Detection of WT1 gene transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia, 12, 1886-1894.
12. Gaiger, A., Linnerth, B., Mann, G., Schmid, D., Heinze, G., Tisljar, K., Haas, O.A., Gadner, H. & Lion, T. (1999) Wilms' tumor gene (WT1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukemia treated by an intensive chemotherapy protocol. European Journal of Hematology, 63, 86-93.
13. Grimwade, D. (1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 106, 591-613.
14. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Barnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MPC AML 10 trial. Blood, 92, 2322-2333.
15. Guerrasio, A., Pilatrino, C., De Micheli, D., Cilloni, D., Serra, A., Gottardi, E., Parziale, A., Marmont, F., Diverio, D., Divona, M., Lo Coco, F. & Saglio, G. (2002) Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia, 16, 1176-1181.
16. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Dohy, H., Nakauchi, H., Ishidate, T., Akiyama, T. & Kishimoto, T. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-3079.
17. Inoue, K., Ogawa, H., Yamagami, T., Soma, T., Tani, Y., Tatekawa, T., Oji, Y., Tamaki, H., Kyo, T., Dohy, H., Hiraoka, A., Masaoka, T., Kishimoto, T. & Sugiyama, H. (1996) Long term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood, 88, 2267-2278.
18. Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., Tatekawa, T., Soma, T., Kishimoto, T. & Sugiyama, H. (1997) Aberrant over-expression of Wilms tumor gene in human leukemia. Blood, 89, 1405-1412.
19. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
20. Kreuzer, K.A., Saborowski, A., Lupberger, J., Appelt, C., Na, I.K., le Coutre, P. & Schmidt, C.A. (2001) Fluorescent 5-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: Implications for monitoring human leukaemias. British Journal of Haematology, 114, 313-318.
21. Liu Yin, J.A. & Tobal, K. (1999) Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance. British Journal of Haematology, 106, 578-590.
22. + progenitors. Blood, 90, 4230-4232.
23. Menssen, H.D., Renkl, H.-J., Rodeck, U., Mayrer, J., Notter, M., Schwartz, S., Reinhardt, R. & Thiel, E. (1995) Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia, 9, 1060-1067.
24. Miwa, H., Beran, M. & Saunders, G.F. (1992) Expression of Wilm's tumor gene in human leukemias. Leukemia, 6, 405-409.
25. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffier, H.P. & Miyoshi, I. (1993) Expression of candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia, 7, 970-977.
26. Patmasiriwat, P., Fraizer, G., Kantarjian, H. & Saunders, G.F. (1999) WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia, 13, 891-900.
27. San Miguel, J.F., Martinez, A., Macedo, A., Vidriales, M.B., Lopez-Berges, C., Gonzalez, M., Caballero, D., Garcia-Marcos, M.A., Ramos, F., Fernandes-Calvo, J., Calmuntia, M.J., Diaz-Mediavilla, J. & Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 2465-2470.
28. Schmid, D., Heinze, G., Linnerth, B., Tisljar, K., Kusec, R., Geissler, K., Sillaber, C., Laczika, K., Mitterbauer, M., Zochbauer, S., Mannhalter, C., Haas, O.A., Lechner, K., Jager, U. & Gaiger, A. (1997) Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia, 11, 639-643.
29. Tobal, K. & Liu Yin, J.A. (1996) Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML M2 with t(8:21). Blood, 88, 3704-3709.
30. Tobal, K., Newton, J., Macheta, M., Chang, J., Morgenstern, G., Evans, P.A., Morgan, G., Lucas, G.S. & Liu Yin, J.A. (2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8:21) can identify patients in durable remission and predict clinical relapse. Blood, 95, 815-819.